Health Care & Life Sciences » Biotechnology | Regulus Therapeutics Inc.

Regulus Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
18,668.00
56,680.00
55,748.00
81,836.00
71,905.00
48,709
Depreciation, Depletion & Amortization
1,360.00
1,490.00
1,591.00
2,276.00
2,524.00
2,262
Other Funds
-
-
-
167.00
-
6,345
Funds from Operations
11,313.00
34,418.00
35,408.00
64,979.00
60,790.00
40,102
Changes in Working Capital
17,017.00
5,092.00
14,451.00
8,097.00
2,017.00
3,171
Net Operating Cash Flow
28,330.00
39,510.00
49,859.00
56,882.00
58,773.00
43,273
Capital Expenditures
835.00
1,211.00
1,430.00
966.00
319.00
Purchase/Sale of Investments
40,054.00
27,996.00
22,905.00
36,277.00
14,255.00
Net Investing Cash Flow
40,889.00
29,207.00
21,475.00
35,311.00
13,936.00
Issuance/Reduction of Debt, Net
100.00
142.00
155.00
19,768.00
-
Net Financing Cash Flow
46,474.00
88,237.00
7,017.00
20,552.00
43,415.00
Net Change in Cash
22,745.00
19,520.00
21,367.00
1,019.00
1,422.00
Free Cash Flow
29,130.00
40,656.00
51,222.00
57,795.00
59,076.00
Change in Capital Stock
46,574.00
88,379.00
7,172.00
951.00
43,415.00

About Regulus Therapeutics

View Profile
Address
10628 Science Center Drive
San Diego California 92121
United States
Employees -
Website http://www.regulusrx.com
Updated 07/08/2019
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.